MAZE Stock Analysis: Maze Therapeutics, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.251m USD | 12M Return: 19.9% | US5787841007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.8M
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 1.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing oral small molecule precision medicines for kidney and metabolic diseases. The company was incorporated in 2017 (formerly Modulus Therapeutics) and completed its IPO on January 31, 2025. Its lead clinical assets include MZE829, a Phase II oral APOL1 inhibitor for APOL1 kidney disease, and MZE782, a Phase II-ready candidate targeting phenylketonuria and chronic kidney disease. Additional pipeline programs include MZE001 for Pompe disease, with development and commercialization rights licensed to Shionogi.
The company supports its research operations through multiple discovery and commercialization partnerships, including agreements with Trace Neuroscience (UNC13A targets), Shionogi (MZE001), and Neurocrine Biosciences (ATXN2 program). As a clinical-stage firm in the pharmaceuticals sub-industry, Maze Therapeutics relies on a small-molecule, target-driven development model typical of precision medicine companies, where revenue is not yet generated from approved products but is supplemented by milestone payments, royalties, and collaboration funding from larger biopharma partners.
- MZE829 Phase II APOL1 kidney disease data readout
- Shionogi partnership monetizes MZE001 Pompe program
- Cash runway from IPO funds pipeline through key milestones
| Net Income: -133.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA 15.60 > 1.0 |
| NWC/Revenue: 1.99k% < 20% (prev 10.1k%; Δ -8.06k% < -1%) |
| CFO/TA -0.20 > 3% & CFO -106.5m > Net Income -133.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 18.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.0m) vs 12m ago 34.54% < -2% |
| Gross Margin: 87.98% > 18% (prev -13.04%; Δ 101.0% > 0.5%) |
| Asset Turnover: 4.79% > 50% (prev 0.82%; Δ 3.97% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.75 (Total Current Assets 420.4m - Total Current Liabilities 23.0m) / Total Assets 531.6m |
| B: -1.05 (Retained Earnings -558.5m / Total Assets 531.6m) |
| C: -0.35 (EBIT TTM -145.6m / Avg Total Assets 417.6m) |
| D: 5.77 (Book Value of Equity 453.1m / Total Liabilities 78.5m) |
| Altman-Z'' = 5.20 = AAA |
| DSRI: 0.50 (Receivables 2.80m/700k, Revenue 20.0m/2.50m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 10.84 (AQ_t 0.17 / AQ_t-1 0.02) |
| SGI: 8.0 (Revenue 20.0m / 2.50m) |
| TATA: -0.05 (NI -133.6m - CFO -106.5m) / TA 531.6m) |
| Beneish M = 7.41 (Cap -4..+1) = D |
As of September 23, 2026, the stock is trading at USD 28.38 with a total of 3,566,261 shares traded. Over the past week, the price has changed by +17.13%, over one month by -4.12%, over three months by +10.99% and over the past year by +19.90%.
Current recommended Stop Loss: 25.90 (which is 8.7% or 1.8 ATR below the current price).
Maze Therapeutics, Common has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy MAZE.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62.6 | 120.4% |
P/E Forward = 8.5324
P/S = 62.5484
P/B = 2.7608
Revenue TTM = 20.0m USD
EBIT TTM = -145.6m USD
EBITDA TTM = -143.7m USD
Long Term Debt = 39.0m USD (from longTermDebt, last quarter)
Short Term Debt = 4.88m USD (from shortTermDebt, last quarter)
Debt = 81.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 21.5m
Net Debt = -329.2m USD (calculated: Debt 81.9m - CCE 411.1m)
Enterprise Value = 921.8m USD (1.25b + Debt 81.9m - CCE 411.1m)
Interest Coverage Ratio = unknown (Ebit TTM -145.6m / Interest Expense TTM 0.0)
EV/FCF = -8.72x (Enterprise Value 921.8m / FCF TTM -105.8m)
FCF Yield = -11.47% (FCF TTM -105.8m / Enterprise Value 921.8m)
FCF Margin = -528.8% (FCF TTM -105.8m / Revenue TTM 20.0m)
Net Margin = -668.0% (Net Income TTM -133.6m / Revenue TTM 20.0m)
Gross Margin = 87.98% ((Revenue TTM 20.0m - Cost of Revenue TTM 2.40m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.73 (Enterprise Value 921.8m / Total Assets 531.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 81.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -115.0m (EBIT -145.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.70 (Total Current Assets 420.4m / Total Current Liabilities 25.2m)
Debt / Equity = 0.18 (Debt 81.9m / totalStockholderEquity, last quarter 453.1m)
Debt / EBITDA = 2.29 (negative EBITDA) (Net Debt -329.2m / EBITDA -143.7m)
Debt / FCF = 3.11 (negative FCF - burning cash) (Net Debt -329.2m / FCF TTM -105.8m)
Total Stockholder Equity = 382.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.99% (Net Income -133.6m / Total Assets 531.6m)
RoE = -34.94% (Net Income TTM -133.6m / Total Stockholder Equity 382.3m)
RoCE = -34.57% (EBIT -145.6m / Capital Employed (Equity 382.3m + L.T.Debt 39.0m))
RoIC = -22.44% (negative operating profit) (NOPAT -115.0m / Invested Capital 512.5m)
WACC = 9.60% (E(1.25b)/V(1.33b) * Re(10.23%) + D(81.9m)/V(1.33b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 70.53 | Cagr: 14.16%
[DCF] Fair Price = unknown (Cash Flow -105.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.75 | Chg30d=+0.47% | Revisions=-10% | Analysts=8
EPS current Year (2026-12-31): EPS=-2.73 | Chg30d=-2.05% | Revisions=+0% | GrowthEPS=+10.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.18 | Chg30d=+0.41% | Revisions=+10% | GrowthEPS=-16.5% | GrowthRev=-55.8%
[Analyst] Revisions Ratio: +0% (up=10, down=10)